SCHEMBL1269611

SCHEMBL1269611

CCOC(=O)CSc1ccc2ccccc2c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ PRNP P04156 2/20 0.59
▸ MAPT P10636 8/20 0.57
▸ GAA P10253 3/20 0.57
▸ ANPEP P15144 1/20 0.56
▸ LMNA P02545 2/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.52
▸ ALDH1A1 P00352 6/20 0.51
▸ POLB P06746 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ L3MBTL1 Q9Y468 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5278158 0.84 ANPEP (0.64) MEN1KMT2APRNPMAPTGAA
SCHEMBL14721112 0.83 LMNA (0.54) MEN1KMT2APRNPMAPTLMNA
SCHEMBL6345753 0.82 CNR2 (0.53) MEN1KMT2APRNPMAPTGAA
SCHEMBL2027600 0.82 LMNA (0.59) MEN1KMT2APRNPMAPTLMNA
SCHEMBL28468678 0.81 KDM4E (0.49) MEN1KMT2APRNPLMNAALDH1A1
SCHEMBL7368226 0.80 CNR2 (0.57) MEN1KMT2APRNPMAPTGAA
SCHEMBL17785160 0.79 LMNA (0.50) MEN1KMT2APRNPMAPTLMNA
SCHEMBL1269574 0.78 ANPEP (0.65) MEN1KMT2AMAPTGAAANPEP
SCHEMBL3162185 0.78 L3MBTL1 (0.60) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL12058772 0.78 ESR1 (0.47) MEN1KMT2APRNPLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG MEN1 4841/4885KMT2A 1448/4885PRNP 4308/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG MEN1 4841/4885KMT2A 1448/4885PRNP 4308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback